Imfinzi

Chemical Namedurvalumab
Dosage FormInjection (intravenous; 500 mg/10 mL, 120 mg/2.4 mL)
Drug ClassMonoclonal antibodies
SystemUrinary, Respiratory
CompanyAstraZeneca
Approval Year2017

Indication

  • For the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy.
  • For the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
  • For the treatment of adult patients with unresectable, Stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Imfinzi (durvalumab) Prescribing Information2020AstraZeneca Pharmaceuticals LP, Wilmington, DE
Document TitleYearSource
Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology.2017Journal of the National Comprehensive Cancer Network